EXECUTIVE SUMMARY

Modelling estimates of the incremental effectiveness & cost-effectiveness of HPV vaccination

Marc Brisson[1,2,3]

Mark Jit[4,5]

Marie-Claude Boily[3]

Jean-Francois Laprise[1]

Dave Martin[1]

Mélanie Drolet[1]

Michel Alary[1,2]

Élodie Bénard[1,2]

1. Centre de recherche du CHU de Québec – Université Laval, Axe santé des populations et pratiques optimales en santé, Québec, Canada
2. Université Laval, Québec, Canada
3. Imperial College, Department of Infectious Disease Epidemiology, London, UK
4. London School of Hygiene & Tropical Medicine London, UK
5. Public Health England, London, UK

Organization:

CHU de Québec – Université Laval
Centre de recherche, Axe santé des populations et pratiques optimales en santé
11, côte du Palais, Québec (QC) G1R 2J6

Table of content

BACKGROUND

Since 2007, 65 out of 195 countries worldwide have implemented human papillomavirus vaccination (HPV)[1, 2]. A recent systematic review and meta-analysis of the observed population-level impact of HPV vaccination has provided compelling empirical evidence from high income countries (HIC). This evidence suggests that girls-only HPV vaccination programs are 1) effective at the population-level and 2) provide herd effects against HPV 16/18 infection and anogenital warts, and 3) that the impact of vaccination follows a dose-response relationship with vaccination coverage (i.e., greater effects with higher coverage/greater percent of the population that is vaccinated)[3]. More specifically, in countries with high vaccination coverage among girls (≥ 50%), significant decreases in HPV-16/18 infections (reduction of 68%), anogenital warts (reduction of 61% vs pre-vaccination) and CIN2+ lesions (reduction of 31%) have been observed in girls aged 15-19 years, over the first 4 years of vaccination[3]. Significant reductions were also noted for older women aged 20-24. Among boys aged 15-19 years old, anogenital warts decreased significantly by 34% and new data from Australia show non-significant decreases in HPV-16/18 (reduction of 63%) between the pre- and post-vaccination periods[4]. In countries with lower coverage among girls (<50%), significant decreases were observed for HPV-16/18 infections (reduction of 50% vs pre-vaccination) and anogenital warts (reduction of 14%) among girls 15-19 years of age, but no significant herd effects were observed. The systematic review did not identify differences between the bivalent and quadrivalent HPV vaccines in their population-level effectiveness against HPV-16/18, and HPV-31/33/45; all the studies were conducted prior to the introduction of the nonavalent vaccine.

At this time, there is very little empirical data on the added population-level impact of a gender-neutral compared to a girls-only HPV vaccination program. A recent update of the systematic review of the population-level impact of HPV vaccination identified eligible studies in only 3 countries (Australia, USA and Canada) having recently implemented gender-neutral programs [5]. Unfortunately, the maximum follow-up available in the identified eligible articles was 1-2 years following a switch from girls-only to gender neutral vaccination, which makes it impossible to measure the added impact of vaccinating boys. In addition, the updated systemic review was unable to isolate the population-level impact of vaccinating multiple age cohorts (which can amount to catch-up vaccination when implemented outside of the primary age target of 9-13 years) from routine immunization of a single cohorts, as the great majority of countries with high vaccination coverage (6/8) also have included catch-up vaccination (i.e., too few countries with no catch-up for comparisons). Finally, the systematic review did not find studies comparing pre- and post-vaccination periods from low to middle income countries (LMIC).

There are, thus, many remaining questions: What is the incremental effectiveness and cost-effectiveness of 1) different HPV vaccines based on girls-only immunization, 2) gender-neutral vs girls-only HPV immunization, and 3) vaccinating multiple age cohorts versus a single age cohort in HIC and LMIC? Mathematical models provide a formal framework to examine these questions, which cannot be answered in trials, or, for the time being, in post-introduction impact evaluations.

OBJECTIVES

We used mathematical modeling and literature reviews to examine the potential incremental effectiveness and cost-effectiveness of:

   a. <u>different HPV vaccines</u> for girls-only vaccination (cervical cancer prevention)
   b. <u>gender-neutral</u> vs girls-only vaccination (prevention of HPV-related diseases)
   c. <u>multiple female cohorts</u> (multiple age cohorts within a defined age range) compared to single age cohort immunization of girls aged 9–13 years (cervical cancer prevention)

METHODS

Results for HIC are mainly based on a systematic review and meta-analysis of transmission-dynamic modeling studies (published between 2009-2015) that predicted the population-level impact of vaccination on HPV6/11/16/18 infections in high-income countries[6]. Additional results are based on HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation). The model has been extensively described [7-9] and has been used to inform previous HPV vaccine policy decisions in the United States and Canada [8-13]. HPV-ADVISE is an individual-based transmission-dynamic model of HPV infection and disease. It includes 18 HPV genotypes (including the 9 types in the 9-valent vaccine: 6/11/16/18/31/33/45/52/58). In addition, a literature review was conducted to identify previously published cost-effectiveness studies of HPV vaccination.

For LMIC, population-level effectiveness and cost-effectiveness predictions are based on two models: HPV-ADVISE LMIC and PRIME (Papillomavirus Rapid Interface for Modelling and Economics)[14]. For HPV-ADVISE LMIC, HPV-ADVISE was calibrated to India, Vietnam, Uganda, Tanzania, and Benin, using comprehensive demographic, sexual behavior and epidemiological data available from international databases (Demographic and Health Surveys (DHS)[15], ICO information Centre on HPV and Cancer[16], Multiple Indicator Survey (MICS)[17], United Nations Statistics Division[18], HIV and AIDS HUB for Asia Pacific-Evidence to action[19]; WHO Global Health Observatory data repository[20]) and original studies[21-26]. PRIME (Papillomavirus Rapid Interface for Modelling and Economics) is a static proportional impact model developed in collaboration with WHO to estimate the impact and cost-effectiveness of introducing HPV vaccination to girls prior to sexual debut in 94 of the original 179 countries across the world[14].

SUMMARY OF FINDINGS
Girls-only immunization

Girls-only HPV vaccination (vs no vaccination):

- <u>Population-level effectiveness</u>. The systematic review and meta-analysis, representing pooled predictions from 16 independent transmission-dynamic models from 10 HIC[6], suggests that HPV vaccination will produce strong herd effects leading to substantial long-term reductions in HPV infection and related diseases in unimmunized women and men (Figure 1). Herd effects are predicted even with vaccination coverage as low as 40%, and to be greater for HPV18, HPV6 and HPV11 than

HPV16 (Figure 1). Results from HPV-ADVISE LMIC (India, Vietnam, Uganda, Tanzania, and Benin) are consistent with those from the HIC models.

- Cost-effectiveness. Despite variations in methods, modeling studies from HIC[27-41] and LMIC (PRIME)[14] are producing consistent conclusions. At current prices of the 2- and 4-valent vaccines, girls-only vaccination is cost-effective (vs no vaccination) irrespective of the vaccine used, even when assuming no cross-protection or herd protection. In a global analysis using PRIME[14], girls-only vaccination was cost-effective even when including only the direct impact on vaccinated women and cervical cancer as an outcome, and using different cost-effectiveness thresholds.
- The main driver of the population-level benefit and cost-effectiveness of Girls-only HPV vaccination is the prevention of HPV-16/18 related cervical cancer.

9-valent Girls-only vaccination (vs 2- or 4-valent)

- Very few modeling studies have examined the incremental population-level effectiveness and cost-effectiveness of 9-valent vaccination vs 2- or 4-valent vaccination[10, 12, 42-45].
- Population-level effectiveness. Current models from HIC[10, 12, 42-44] and LMIC (PRIME)[14] predict that switching to a 9-valent vaccination strategy would further reduce precancerous cervical lesions and cervical cancer, with very little impact on non-cervical HPV-related outcomes. However, importantly, the magnitude of the incremental benefits of the 9-valent at preventing cervical cancer outcomes strongly depends on assumptions regarding the level and duration of cross-protection provided by 2- or 4-valent vaccines.
- Cost-effectiveness. In HIC, switching to a 9-valent program is predicted to be cost-effective in Canada, Austria, and cost saving in the U.S., if the cost/dose of the 9-valent is assumed to be 10-15% greater than the 4-valent [10, 12, 42-44]. In a global analysis using PRIME[14], Girls-only 9-valent vaccination was estimated to be cost-effective in LMIC (vs 2-valent or 4-valent, using 1xGDP as the cost-effectiveness threshold), assuming 2-dose vaccination and the cost/dose of the 9-valent was in the same range as the 2- and 4-valent vaccines. The 9-valent was not cost-effective (vs 2-valent), under assumptions of maximum cross-protection for the 2-valent vaccine.

Gender-neutral immunization

- Population-level effectiveness. Given the predicted substantial herd effects of Girls-only vaccination when coverage is moderate to high, the incremental benefit of vaccinating adolescent boys is predicted to be limited in HIC (Figure 1a - Systematic review of models in HIC). Results from LMIC suggest that Girls-only vaccination may produce lower herd–effects than in HIC (Figure 1b, example for HPV-ADVISE INDIA). However, this result depends on sexual behaviour, which is highly variable between LMIC. In some LMIC, where a large proportion of females marry (having had no pre-marital sex partners) and have no other sexual partner in their lifetime. In these countries, HPV transmission is predicted to be through the husbands who have concurrent partnerships or are clients of sex workers. In these cases, gender-neutral vaccination that includes adolescent boys may provide

substantial benefits for women (in particular if vaccination coverage is low among at-risk girls who are harder to reach with vaccination).

- Potential for HPV elimination: Importantly, the majority of models in the systematic review predict that vaccinating boys in addition to girls in HIC could eliminate HPV16/18/6/11, provided 80% coverage is achieved in both sexes and the vaccine confers long-term protection (Figure 1a). This result was not found in the LMIC that were modelled (Figure 1b, example for HPV-ADVISE INDIA)).

- Cost-effectiveness: Models from HIC have consistently shown that, if the HPV vaccination coverage in girls is greater than approximately 50%, gender-neutral vaccination is unlikely to be cost-effective (vs Girls-only vaccination [40, 41].

- The epidemiological and economic considerations about vaccinating boys should focus on the following issues: 1) the feasibility and incremental marginal costs of increasing vaccination coverage among girls versus introducing a gender-neutral program[46], 2) whether the price of the vaccine can be sufficiently reduced for boys in order for the strategy to be cost-effective, and 3) importance placed on achieving equal protection for MSM.

**Single and multiple age cohort immunization**

- Population-level effectiveness. In HIC and LMIC, vaccinating multiple age cohorts is predicted to result in a substantially shorter time in achieving the impact of the vaccination than vaccination of single age cohorts (Figure 1). However, the impact of multiple age cohort vaccination could be reduced in countries with early age at HPV infection.

- Cost-effectiveness. In a global analysis using PRIME, vaccinating multiple cohorts of girls is cost-effective in the age range of 9–14 years (vs single age cohort), particularly when a 2-dose schedule is used. The incremental cost-effectiveness for additional age cohort of girls and women aged ≥15 years is reduced as 3-dose schedule are required and proportionally more girls/women will already have been infected.

FIGURE 1. Population-level impact and herd effects of Girls-only and Girls&Boys HPV vaccination.

A) High income Countries - Pooled predictions from 16 models.

**B) Low to Middle Income Country (India) -** Predictions from HPV-ADVISE INDIA

Relative reduction of HPV prevalence among women and men following 70 years of Girls-Only and Girls&Boys vaccination. Herd effects=reduction of HPV prevalence in Men with Girls-only vaccination. Girls-Only: Vaccination of girls only; Girls&Boys: Vaccination of girls and boys. The pooled estimates represent median and 10th, 25th, 75th, and 90th percentiles of the predictions of the 16 models in the systematic review (Figure 1A) and the best fitting parameter sets for HPV-ADVISE INDIA (Figure 1B). Predictions were performed using the following vaccine characteristics: Vaccine efficacy=100% and Duration of vaccine protection=Lifelong.

FIGURE 2. Population-level impact of single and multiple age cohort Girls-only HPV vaccination.

A) High income Countries (Canada) - Predictions from HPV-ADVISE Canada

B) Low to Middle Income Country (India) - Predictions from HPV-ADVISE INDIA

Reduction of HPV-16/18 prevalence and cervical cancer among women over time since vaccination. Girls-Only: Vaccination of girls only. Predictions were performed using the following vaccine characteristics: Vaccination coverage=80-%, Vaccine efficacy=95%, and Duration of vaccine protection=Lifelong.

REFERENCES

1. Brotherton J, Bloem P. HPV Vaccination: Current Global Status. *Current Obstetrics and Gynecology Reports* 2015; 4(4): 220-33.
2. World Health Organization. Countries with HPV vaccine in the national immunization programme and planned introductions. World Health Organization/IVB Database. January 2014. http://www.who.int/immunization/diseases/hpv/decision_implementation/en/, Accessed September 2014.
3. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* 2015; 15(5): 565-80.
4. Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. *Lancet Infect Dis* 2016. doi: 10.1016/S1473-3099(16)30116-5.
5. Drolet M, Bénard É, Brisson M. Population-level impact and herd effects following papillomavirus immunization programmes: a systematic review and meta-analysis. Executive Summary. Immunization, Vaccines and Biologicals. SAGE meeting, October 18-20, 2016, Geneva.
6. Brisson M, Bénard E, Drolet M, et al. Population-level impact, herd immunity and elimination after HPV vaccination: a systematic review and meta-analysis of predictions of transmission-dynamic models. *Lancet Public Health* 2016; http://dx.doi.org/10.1016/S2468-2667(16)30001-9: 1-10.
7. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. *Vaccine* 2010; 28(33): 5473-84.
8. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. *J Natl Cancer Inst* 2012; 104(22): 1712-23.
9. Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. *Vaccine* 2013; 31(37): 3863-71.
10. Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. *Int J Cancer* 2014; 134(9): 2264-8.
11. Laprise JF, Drolet M, Boily MC, et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. *Vaccine* 2014; 32(44): 5845-53.
12. Brisson M, Laprise JF, Chesson HW, et al. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. *J Natl Cancer Inst* 2016; 108(1).
13. Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. *J Infect Dis* 2016; 214(5): 685-8.
14. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. *Lancet Global Health* 2014; 2: e406-14.
15. DHS Program. The Demographic and health surveys program. Available at http://dhsprogram.com/. Accessed September 2016.
16. HPV information centre. ICO (institut Catala d'Oncologia) Information Centre on HPV and Cancer. Available at http://www.hpvcentre.net/. Accessed September 2016.
17. Unicef. Multiple Indicator Cluster Survey (MICS). Statistics and Monitoring. Available at http://www.unicef.org/statistics/index_24302.html. Accessed September 2016.
18. United Nations Statistics Division. UNSD Statistical Databases. Available at http://unstats.un.org/unsd/databases.htm. Accessed September 2016.
19. HIV and AIDS Data Hub for Asia Pacific. Evidence to Action - Data sheets. Available at http://www.aidsdatahub.org/Data-Sheets. Accessed September 2016.
20. World Health Organization. Global Health Observatory data repository. Availble at http://apps.who.int/gho/data/node.home. Accessed September 2016.
21. Lowndes CM, Jayachandran AA, Banandur P, et al. Polling booth surveys: A novel approach for reducing social desirability bias in HIV-related behavioural surveys in resource-poor settings. AIDS Behav 2012; 16: 1054-62.
22. Munro HL, Pradeep BS, Jayachandran AA, et al. Prevalence and determinants of HIV and sexually transmitted infections in a general population-based sample in Mysore district, Karnataka state, southern India. *AIDS* 2008; 22 Suppl 5: S117-25.
23. Behanzin L, Diabate S, Minani I, et al. Assessment of HIV-related risky behaviour: a comparative study of face-to-face interviews and polling booth surveys in the general population of Cotonou, Benin. *Sex Transm Infect* 2013; 89(7): 595-601.

24. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. *Lancet* 2006; 368(9548): 1706-28.
25. Vandepitte J, Lyerla R, Dallabetta G, Crabbe F, Alary M, Buve A. Estimates of the number of female sex workers in different regions of the world. *Sex Transm Infect* 2006; 82 Suppl 3: iii18-25.
26. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. *PLoS Med* 2008; 5(6): e132.
27. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. *Vaccine* 2007; 25(29): 5399-408.
28. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. *IntJ TechnolAssessHealth Care* 2008; 24(1): 10-9.
29. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. *Emerg Infect Dis* 2007; 13(1): 28-41.
30. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. *Emerg Infect Dis* 2004; 10(11): 1915-23.
31. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. *J Natl Cancer Inst* 2004; 96(8): 604-15.
32. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. *EmergInfectDis* 2003; 9(1): 37-48.
33. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. *Jama* 2003; 290(6): 781-9.
34. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. *EmergInfectDis* 2008; 14(2): 244-51.
35. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. *BMJ* 2008; 337: a769.
36. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. *N Engl J Med* 2008; 359(8): 821-32.
37. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. *Cost Eff Resour Alloc* 2008; 6: 4.
38. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. *BJOG* 2008; 115(8): 947-56.
39. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. *Curr Med Res Opin* 2008; 24(5): 1473-83.
40. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. *Public Health Genomics* 2009; 12(5-6): 343-51.
41. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. *Vaccine* 2012; 30 Suppl 5: F157-67.
42. Chesson HW, Laprise JF, Brisson M, Markowitz LE. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. *J Infect Dis* 2016; 213(11): 1694-700.
43. Weiss T, Pillsbury M, Dasbach EJ. Potential health and economic impact of the 9-valent HPV vaccine in the United States. Abstract presented at the 29th International Papillomavirus Conference and Public Health & Clinical Workshops. Seattle, United Stated, August 21-25 2014.
44. Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. *BMC Infect Dis* 2016; 16: 153.
45. Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. *PLoS One* 2014; 9(9): e106836.
46. Ryser MD, McGoff K, Herzog DP, Sivakoff DJ, Myers ER. Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. *Epidemics* 2015; 11: 32-47.